10-Q · August 7, 2026
Q2 2026 operating results showed a favorable trend, with revenue of $63.693 million and diluted EPS of $2.37, both materially above Q1 2026 and Q2 2025 levels. The company also completed a $60.0 million share repurchase…
Earnings analysis · 10-Q
LGND earnings analysis
Filed October 30, 2026 · Our reading of the company's report
The latest report
Ligand delivered a strong third quarter, with revenue of $78.7 million and adjusted EPS of $2.67 beating estimates by 1.9% and 24.2%, respectively. Royalty revenue increased 51% year over year to $70.3 million,…
Read full summary
Ligand delivered a strong third quarter, with revenue of $78.7 million and adjusted EPS of $2.67 beating estimates by 1.9% and 24.2%, respectively. Royalty revenue increased 51% year over year to $70.3 million, supported by the XOMA acquisition and Filspari, and management raised 2026 adjusted EPS guidance to $9.50-$9.75 while reaffirming revenue guidance of $270-$310 million. Offsetting risks include the integration of the July 14, 2026 XOMA acquisition, potential royalty buyouts, unresolved Viking litigation, and obligations related to the 2030 and 2031 Notes.
Where revenue came from
The business segments reported by the company.
Shares of the segments disclosed in this filing, largest first.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $2.67
What stood out
-
Revenue beat estimates
Third-quarter revenue was $78.7 million versus $77.2 million estimated, a $1.5 million or 1.9% beat. Revenue increased approximately 23% from $64 million in 2026 Q2 but declined approximately 32% from $115 million in 2025 Q3.
-
Strong EPS outperformance
Adjusted diluted EPS was $2.67 versus $2.15 estimated, a $0.52 or 24.2% beat. EPS increased from $2.22 in 2026 Q2 but declined from $5.68 in 2025 Q3.
-
Royalty revenue surged
Royalty revenue rose 51% year over year to $70.3 million, with management attributing momentum to the XOMA acquisition and Filspari.
-
Full-year EPS outlook raised
Management raised 2026 adjusted diluted EPS guidance to $9.50-$9.75 from $9.00-$9.50, while reaffirming total revenue guidance of $270-$310 million.
-
XOMA expands royalty portfolio
The company completed the XOMA Acquisition on July 14, 2026, expanding its royalty portfolio and contributing to the 51% year-over-year increase in royalty revenue to $70.3 million.
-
Controls remained effective
Management concluded that disclosure controls were effective as of September 30, 2026, and reported no changes during the quarter that materially affected internal control over financial reporting.
What to watch
-
Royalty buyouts could reduce revenue
The filing adds a risk that licensees or sublicensees may reduce, buy down, or buy out royalty obligations for predetermined amounts that may be below the net present value of future royalties, potentially reducing recurring revenue. The risk applies to arrangements with contractual buyout rights and could materially affect results.
-
XOMA integration execution risk
Ligand warns that it may not successfully integrate the XOMA Royalty business acquired on July 14, 2026. Integration could increase costs, divert management attention, or delay realization of expected benefits from the expanded royalty portfolio.
-
Debt service and liquidity risk
The company states that its ability to service the 2030 Notes and 2031 Notes depends on future cash flow and may require asset sales, debt restructuring, or dilutive financing if cash generation is insufficient. Holders may also require cash repurchase upon specified events, including a fundamental change.
-
Viking litigation remains unresolved
Viking filed a cross-complaint on July 2, 2026 asserting 3 causes of action related to Ligand's termination of the TR-Beta Program. The matter is at an early stage, with a demurrer hearing scheduled for February 26, 2027, and potential losses not estimable.
-
Potential XOMA transaction litigation
The company disclosed potential litigation in connection with the XOMA Acquisition and stated that it does not currently expect such litigation to have a material adverse effect. The acquisition was completed on July 14, 2026, but the outcome of any such proceedings is inherently uncertain.
Management's outlook
2026 adjusted diluted EPS guidance was raised to approximately $9.50-$9.75 from $9.00-$9.50, while total revenue guidance was reaffirmed at $270-$310 million.
Earlier filings 2
10-Q · May 8, 2026
Ligand Pharmaceuticals posted Q1 2026 results showing revenue of $51.7 million, reflecting a 14% increase year-over-year but below estimates by approximately 12%. Gross margins remain robust at 95%, and the company…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.